🇺🇸 FDA
Pipeline program

Crinecerfont

NBI-74788-CAH2008

Phase 2 small_molecule completed

Quick answer

Crinecerfont for CAH - Congenital Adrenal Hyperplasia is a Phase 2 program (small_molecule) at NEUROCRINE BIOSCIENCES INC with 1 ClinicalTrials.gov record(s).

Program details

Company
NEUROCRINE BIOSCIENCES INC
Indication
CAH - Congenital Adrenal Hyperplasia
Phase
Phase 2
Modality
small_molecule
Status
completed

Clinical trials